CD274 and neoplasm: KEYNOTE-024 trail revealed that a fixed dose of Pembrolizumab (200 mg) was associated with the improved OS and PFS and lower treatment-related adverse events in NSCLC patients with PD-L1 tumour proportion score (TPS) ≥50% in comparison with chemotherapy [86].